Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
2/54 von 416    DIMDI: MEDLINE (ME60) © NLM
ND: ME16756221
PMID: 16756221
LR: 20061115
CED: 20060607
DCO: 20060717
Autoren: Lems WF; Bijlsma JW
Titel: Effectiviteit van voedingssupplementen bij artrose: de twijfel blijft.
Effectiveness of dietary supplements in patients with osteoarthritis: the doubt persists
Quelle: Nederlands tijdschrift voor geneeskunde; VOL: 150 (20); p. 1105-7 /20060520/
PM: Print
SU: IM
Sprache: Dutch
CY: Netherlands
JID: 0400770
ISSN: 0028-2162
CO: NETJAN
Institution: VU Medisch Centrum, afd Reumatologie 4A42, Amsterdam. wf.lems@vumc.nl
DT: English Abstract; Journal Article
Schlagwörter
CT: CHONDROITIN SULFATES/*therapeutic use; DIETARY SUPPLEMENTS/*; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GLUCOSAMINE/*therapeutic use; HUMANS; OSTEOARTHRITIS/*drug therapy; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME
CTG: CHONDROITINSULFATE/*therapeutische Anwendung; NAHRUNGSERGÄNZUNGSMITTEL/*; ARZNEIMITTEL-KOMBINATIONSTHERAPIE; GUTACHTENBASIERTE MEDIZIN; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; OSTEOARTHROSE/*Arzneimitteltherapie; RANDOMISIERTE KONTROLLIERTE STUDIEN; BEHANDLUNGSERGEBNIS
TE: Glucosamine/3416-24-8; Chondroitin Sulfates/9007-28-7
CR: 3416-24-8; 9007-28-7
NOTE: Comment in: Ned Tijdschr Geneeskd. 2006 Aug 12;150(32):1800-1; author reply 1801; Ref.PMID: 16953538
AB: Earlier studies with glucosamines in patients with osteoarthritis have shown conflicting results. A placebo-controlled randomised trial was now carried out in 1583 patients with osteoarthritis. The primary endpoint was a 20% reduction in knee pain between baseline and week 24 according to the 'Western Ontario and McMaster Universities arthritis index'(WOMAC)-score. No statistically significant difference was found between the groups using placebo (60% response), glucosamine (64%), chondroitin sulphate (65%) or combination therapy (67%). The results of this trial do not support the hypothesis that glucosamines have a positive effect on symptoms in patients with osteoarthritis of the knee. However, (a) the chance of a statistically significant difference decreases with increasing magnitude of the placebo response, (b) there was a statistically significant reduction in the patients with moderate to severe pain, (c) when the pain was assessed with the more sensitive 'Outcome measures in rheumatology clinical trials'(OMERACT)-'Osteoarthritis Research Society International'(OARSI)-score, there was a better response in the group given combined treatment, (d) the data on radiological progression and the effects on cartilage markers must still come in, and (e) the efficacy may have been higher ifa different dietary supplement had been used. These questions on the design and the robustness of the study indicate that further studies are necessary.
» Volltext »

» Fenster schließen »